News

Infection in Rheumatic Disease

Researchers conducted a phase 2 multicenter, randomized, controlled trial involving adult patients with chronic HBV infection with virologic suppression with NA therapy to examine 48 weeks of treatment with xalnesiran 100 mg (group 1; 30 patients), xalnesiran 200 mg (group 2; 30 patients), xalnesiran 200 mg + ruzotolimod (group 3; 34 patients), xalnesiran 200 mg + pegylated interferon alfa-2a 180 µg (group 4; 30 patients), or NA alone (group 5; 35 patients).

Practice Management

Based on new immunogenicity data, the FDA changed the label for the Bexsero MenB-4C vaccine from a two-dose schedule at intervals of zero and at least one month to a two-dose schedule at intervals of zero and six months, and added a three-dose schedule (zero, one to two, and six months).